{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:27:26Z","timestamp":1787956046568,"version":"build-2784847793"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.cgh.2025.03.003","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:41:27Z","timestamp":1744285287000},"page":"355-364.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Change in cT1 Following Interventions in MASLD: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7881-4205","authenticated-orcid":false,"given":"Anneli","family":"Andersson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cayden","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Mouchti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Vuppalanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh","family":"Harisinghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Ajaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amreen","family":"Dinani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitava","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Muthiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Pansini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2025.03.003_bib1","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","author":"Loomba","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.03.003_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100727","article-title":"The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010-2020: a population-based study","volume":"27","author":"Hamid","year":"2022","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.cgh.2025.03.003_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dom.14484","article-title":"Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications","volume":"24","author":"Byrne","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cgh.2025.03.003_bib4","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.03.003_bib5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2025.03.003_bib6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.03.003_bib7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","article-title":"Therapeutic landscape of metabolic dysfunction\u2013associated steatohepatitis (MASH)","volume":"24","author":"Do","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cgh.2025.03.003_bib8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3748\/wjg.v27.i7.609","article-title":"Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort","volume":"27","author":"Imajo","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.03.003_bib9","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.03.003_bib10","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1007\/s10620-021-07089-w","article-title":"Incidence of complications from percutaneous biopsy in chronic liver disease: a systematic review and meta-analysis","volume":"67","author":"Thomaides-Brears","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2025.03.003_bib11","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cgh.2018.06.011","article-title":"Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis","volume":"17","author":"Han","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.03.003_bib12","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/hep.32315","article-title":"Placebo effect on progression and regression in NASH: evidence from a meta-analysis","volume":"75","author":"Ng","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2025.03.003_bib13","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.cgh.2021.09.041","article-title":"Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis","volume":"20","author":"Andersson","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.03.003_bib14","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1111\/liv.14625","article-title":"Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease","volume":"40","author":"Jayaswal","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2025.03.003_bib15","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jhep.2023.05.046","article-title":"Liver disease is a significant risk factor for cardiovascular outcomes \u2013 a UK Biobank study","volume":"79","author":"Roca-Fernandez","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2025.03.003_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214921","article-title":"Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver","volume":"14","author":"Bachtiar","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2025.03.003_bib17","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/jmri.29610","article-title":"Quantitative MRI for monitoring metabolic dysfunction-associated steatotic liver disease: a test\u2013retest repeatability study","volume":"61","author":"Beyer","year":"2025","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.cgh.2025.03.003_bib18","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.231092","article-title":"Repeatability of MRI biomarkers in nonalcoholic fatty liver disease: the NIMBLE Consortium","volume":"309","author":"Fowler","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.cgh.2025.03.003_bib19","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jhep.2024.08.031","article-title":"Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH","volume":"82","author":"Alkhouri","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2025.03.003_bib20","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"19","author":"Stine","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.03.003_bib21","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"371","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2025.03.003_bib22","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jphys.2023.05.012","article-title":"Research note: interpreting findings of a systematic review using GRADE methods","volume":"69","author":"Brennan","year":"2023","journal-title":"J Physiother"},{"key":"10.1016\/j.cgh.2025.03.003_bib24","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"386","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2025.03.003_bib25","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2025.03.003_bib26","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2019"},{"key":"10.1016\/j.cgh.2025.03.003_bib27","series-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2009"},{"key":"10.1016\/j.cgh.2025.03.003_bib28","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.21037\/qims-24-148","article-title":"The effectiveness of magnetic resonance imaging (MRI) iron corrected T1 in monitoring metabolic dysfunction\u2013associated steatohepatitis in obesity following bariatric surgery and lifestyle modification: a prospective cohort study","volume":"14","author":"Chiyanika","year":"2024","journal-title":"Quant Imaging Med Surg"},{"key":"10.1016\/j.cgh.2025.03.003_bib29","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/4228321","article-title":"Multiparametric magnetic resonance imaging and magnetic resonance elastography to evaluate the early effects of bariatric surgery on nonalcoholic fatty liver disease","volume":"2023","author":"Tan","year":"2023","journal-title":"Int J Biomed Imaging"},{"key":"10.1016\/j.cgh.2025.03.003_bib30","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/oby.23793","article-title":"A low-energy total diet replacement program demonstrates a favorable safety profile and improves liver disease severity in nonalcoholic steatohepatitis","volume":"31","author":"Koutoukidis","year":"2023","journal-title":"Obesity"},{"key":"10.1016\/j.cgh.2025.03.003_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.202001178","article-title":"Effect of Mastiha supplementation on NAFLD: the MAST4HEALTH randomised, controlled trial","volume":"65","author":"Amerikanou","year":"2021","journal-title":"Mol Nutr Food Res"},{"key":"10.1016\/j.cgh.2025.03.003_bib32","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3390\/biomedicines12102328","article-title":"Comparative analysis of resmetirom vs. FGF21 analogs vs. GLP-1 agonists in MASLD and MASH: network meta-analysis of clinical trials","volume":"12","author":"Ayesh","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.cgh.2025.03.003_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.575843","article-title":"Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis","volume":"11","author":"Dennis","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.cgh.2025.03.003_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2025.03.003_bib35","first-page":"1115A","article-title":"Liver-distributed FXR agonist TERN-101 leads to corrected T1 (cT1) response and a population shift to lower cT1 risk categories in nash phase 2a lift study","volume":"72","author":"Lawitz","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2025.03.003_bib36","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.14309\/ajg.0000000000001375","article-title":"Safety, tolerability, and biologic activity of AXA1125 and AXA1957 in subjects with nonalcoholic fatty liver disease","volume":"116","author":"Harrison","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.03.003_bib37","doi-asserted-by":"crossref","first-page":"S653","DOI":"10.1016\/S0168-8278(23)02005-6","article-title":"Improvements in liver fibroinflammation (as assessed by corrected T1 [cT1]) with HTD1801 (berberine ursodeoxycholate) treatment in patients with non-alcoholic steatohepatitis and type 2 diabetes mellitus","volume":"78","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2025.03.003_bib38","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000542","volume":"79","author":"Noureddin","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2025.03.003_bib39","article-title":"Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: systematic review and network meta-analysis","author":"Koh","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2025.03.003_bib40","first-page":"5018","article-title":"Phase 3 ESSENCE trial\u202f: semaglutide in metabolic dysfunction\u2013 associated steatohepatitis (MASH) (abstract)","volume":"40","author":"Newsome","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2025.03.003_bib41","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cgh.2021.05.059","article-title":"The placebo response in randomized trials in nonalcoholic steatohepatitis simply explained","volume":"20","author":"Rowe","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2025.03.003_bib42","first-page":"A17","article-title":"P21 Obeticholic acid improves hepatic fibroinflammation as assessed by multiparametric MRI: interim results of the REGENERATE trial","volume":"69","author":"Anstee","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2025.03.003_bib43","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2025.03.003_bib44","first-page":"97A","article-title":"Liver-distributed FXR agonist TERN-101 demonstrates favorable safety and efficacy profile in NASH phase 2a LIFT study","volume":"74","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2025.03.003_bibe1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jhep.2024.08.031","article-title":"Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH","volume":"82","author":"Alkhouri","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2025.03.003_bibe2","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.202001178","article-title":"Effect of Mastiha supplementation on NAFLD: the MAST4HEALTH randomised, controlled trial","volume":"65","author":"Amerikanou","year":"2021","journal-title":"Mol Nutr Food Res"},{"key":"10.1016\/j.cgh.2025.03.003_bibe3","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.21037\/qims-24-148","article-title":"The effectiveness of magnetic resonance imaging (MRI) iron corrected T1 in monitoring metabolic dysfunction-associated steatohepatitis in obesity following bariatric surgery and lifestyle modification: a prospective cohort study","volume":"14","author":"Chiyanika","year":"2024","journal-title":"Quant Imaging Med Surg"},{"key":"10.1016\/j.cgh.2025.03.003_bibe4","doi-asserted-by":"crossref","first-page":"e1542","DOI":"10.1210\/clinem\/dgad375","article-title":"Growth hormone administration improves nonalcoholic fatty liver disease in overweight\/obesity: a randomized trial","volume":"108","author":"Dichtel","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cgh.2025.03.003_bibe5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203054","article-title":"Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial","volume":"13","author":"Harrison","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2025.03.003_bibe6","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2025.03.003_bibe7","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.14309\/ajg.0000000000001375","article-title":"Safety, tolerability, and biologic activity of AXA1125 and AXA1957 in subjects with nonalcoholic fatty liver disease","volume":"116","author":"Harrison","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.03.003_bibe8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2025.03.003_bibe9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2025.03.003_bibe10","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/oby.23793","article-title":"A low-energy total diet replacement program demonstrates a favorable safety profile and improves liver disease severity in nonalcoholic steatohepatitis","volume":"31","author":"Koutoukidis","year":"2023","journal-title":"Obesity"},{"key":"10.1016\/j.cgh.2025.03.003_bibe11","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.03.003_bibe12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.03.003_bibe13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2025.03.003_bibe14","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/4228321","article-title":"Multiparametric magnetic resonance imaging and magnetic resonance elastography to evaluate the early effects of bariatric surgery on nonalcoholic fatty liver disease","volume":"2023","author":"Tan","year":"2023","journal-title":"Int J Biomed Imaging"},{"key":"10.1016\/j.cgh.2025.03.003_bibe15","doi-asserted-by":"crossref","unstructured":"Anstee Q, Digpal K. P21 Obeticholic acid improves hepatic fibroinflammation as assessed by multiparametric MRI: interim results of the REGENERATE trial. Gut. 202;69:A17.","DOI":"10.1136\/gutjnl-2020-BASL.32"},{"key":"10.1016\/j.cgh.2025.03.003_bibe16","first-page":"S845","article-title":"2078-A NASH","volume":"78","author":"Gunn","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2025.03.003_bibe17","doi-asserted-by":"crossref","first-page":"S653","DOI":"10.1016\/S0168-8278(23)02005-6","article-title":"Improvements in liver fibroinflammation (as assessed by corrected T1 ecT1.) with HTD1801 (berberine ursodeoxycholate) treatment in patients with non-alcoholic steatohepatitis and type 2 diabetes mellitus","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2025.03.003_bibe18","first-page":"1115A","article-title":"Liver-distributed FXR agonist TERN-101 leads to corrected T1 (cT1) response and a population shift to lower cT1 risk categories in nash phase 2a lift study","volume":"74","author":"Lawitz","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2025.03.003_bibe19","doi-asserted-by":"crossref","first-page":"S715","DOI":"10.1016\/S0168-8278(22)01748-2","article-title":"TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study","volume":"77","author":"Lawitz","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2025.03.003_bibe20","first-page":"97A","article-title":"Liver-distributed FXR agonist TERN-101 demonstrates favorable safety and efficacy profile in NASH phase 2a LIFT study","volume":"74","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2025.03.003_bibe21","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000542","volume":"79","author":"Noureddin","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2025.03.003_bibe22","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(22)01743-3","article-title":"Efficacy and safety of leronlimab in patients with non-alcoholic steatohepatitis: topline results of NASH01 clinical trial","volume":"77","author":"Noureddin","year":"2022","journal-title":"J Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652500254X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652500254X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:43:28Z","timestamp":1779219808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154235652500254X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S154235652500254X"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2025.03.003","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Change in cT1 Following Interventions in MASLD: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2025.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}